Cell transplantation

CXCR4 Anormed III AMD3100 Stem cell transplant ... 

Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvamas J, Forman SJ (2005) Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105 874-878... 

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for SCD. The best candidates are children with SCD who are younger than 16 years of age with severe complications who have an identical H LA-matched donor, usually a sibling. The transplant-related mortality rate is between 5% and 10%, and graft rejection is approximately 10%. Other risks include secondary malignancies, development of seizures or intracranial bleeding, and infection in the immediate posttransplant period.6,25,32,33... 

Walters MC. Novel therapeutic approaches in sickle cell disease. Stem cell transplantation for sickle cell disease How and when to intervene Hematology 2002 22-29. 

Invasive molds, particularly Aspergillus, have become an increasingly important complication of cancer therapy and organ transplantation. Patients with acute leukemia and recipients of allogeneic hematopoietic cell transplants are at especially high risk for invasive aspergillosis due to prolonged neutropenia and deficiencies in cell-mediated immunity associated... 

Varicella VAR 0.5 mL Subcutaneous Allergic reaction to gelatin or neomycin Pregnant women Immunocompromised host Recently received a blood transfusion Hematopoietic stem cell transplant... 

Following hematopoietic stem cell transplantation the patient will need virtually all routine vaccines to be administered again however, the patient will not be able to mount an adequate response for 6 to 12 months post-transplant. Diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, hepatitis B, pneumococcal, and inactivated poliovirus should be given at 12,14, and 24 months post-hematopoietic stem cell transplantation. Inactivated influenza vaccine should be given yearly, starting 6 months after transplant. Measles, mumps and rubella can be given 2 years after transplant and varicella vaccine is contraindicated.16... 

Assess the role of autologous hematopoietic stem cell transplantation in relapsed Hodgkin s lymphoma and non-Hodgkin s lymphoma. 

BCV (high-dose with autologous stem cell transplant)3 Carmustine 400 mg/m2 IV x 1 day Etoposide 800 mg/m2 IV daily x 3 days Cyclophosphamide 1800 mg/m2 IV daily x 4 days... 

BEAM (high-dose with autologous stem cell transplant)3... 

Allogeneic hematopoietic stem cell transplantation (HSCT) has been used in the treatment of pediatric AML in first complete remission. In most clinical trials, the availability of HLA-matched sibling donors determined whether patients underwent HSCT as postremission treatment. To facilitate this process, it is important to obtain HLA typing on all younger patients with AML and siblings shortly after diagnosis. Patients who do not have an HLA-matched sibling will proceed to postremission therapy. 

Allogeneic stem cell transplantation is the only curative treatment for chronic myelogenous leukemia (CML). 

The primary goal in the treatment of multiple myeloma is to decrease tumor burden and minimize complications associated with the disease. A watch and wait approach is an option for asymptomatic patients who have no lytic lesions in the bone. Once symptoms occur, treatment is required. Chemotherapy can be used to reduce tumor burden in patients with symptomatic disease, but increasingly, immunomodula-tors such as thalidomide and dexamethasone are initial therapy. Almost all patients will become refractory to initial treatment and will require the use of salvage therapies such as bortezomib. Autologous stem cell transplantation prolongs overall survival in patients who can tolerate high-dose chemotherapy and may be the treatment of choice for many patients. 

Melphalan (Alkeran) Myelosuppression, secondary malignancies, pulmonary fibrosis, sterility, alopecia Dose of 0.15 mg/kg for 7 days given orally once daily, repeated every 4-6 weeks IV formulation used for stem cell transplantation... 

Discuss whether this patient is a candidate for autologous stem cell transplantation. 

Early in the diagnosis, patients should be evaluated for allogeneic stem cell transplantation. Ideal candidates include younger patients in chronic-phase CML who have an HLA-matched related or unrelated donor. 

Explain the rationale for using hematopoietic cell transplant (HCT) to treat cancer. 

O Hematopoietic cell transplantation (HCT) is a procedure used mainly to treat hematologic malignancies via high-dose chemotherapy and/or a graft-versus-tumor effect. 

---